 Michael Liptay
Concepts (393)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 66 | 2021 | 756 | 8.660 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 48 | 2021 | 374 | 6.440 |
Why?
| | Pneumonectomy | 27 | 2021 | 90 | 3.670 |
Why?
| | Sentinel Lymph Node Biopsy | 9 | 2015 | 21 | 2.350 |
Why?
| | Lymph Nodes | 9 | 2015 | 84 | 2.320 |
Why?
| | Neoplasm Staging | 35 | 2021 | 481 | 1.760 |
Why?
| | Radiopharmaceuticals | 7 | 2009 | 63 | 1.680 |
Why?
| | Thoracic Surgery, Video-Assisted | 5 | 2015 | 22 | 1.180 |
Why?
| | Mesothelioma | 6 | 2012 | 17 | 1.160 |
Why?
| | Adenocarcinoma | 8 | 2014 | 237 | 1.130 |
Why?
| | Esophageal Neoplasms | 4 | 2011 | 61 | 1.020 |
Why?
| | Humans | 93 | 2021 | 31481 | 1.020 |
Why?
| | Lymphatic Metastasis | 13 | 2015 | 107 | 0.990 |
Why?
| | Carcinoma, Squamous Cell | 5 | 2019 | 207 | 0.970 |
Why?
| | Neoadjuvant Therapy | 8 | 2015 | 71 | 0.960 |
Why?
| | Bronchoscopy | 6 | 2019 | 38 | 0.950 |
Why?
| | Pleural Neoplasms | 6 | 2012 | 13 | 0.900 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 4 | 2009 | 8 | 0.880 |
Why?
| | Postoperative Complications | 11 | 2021 | 1083 | 0.840 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2017 | 236 | 0.820 |
Why?
| | Aged | 48 | 2021 | 10295 | 0.780 |
Why?
| | Respiration, Artificial | 1 | 2021 | 116 | 0.780 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2019 | 13 | 0.750 |
Why?
| | False Positive Reactions | 1 | 2019 | 40 | 0.750 |
Why?
| | Unnecessary Procedures | 1 | 2019 | 30 | 0.720 |
Why?
| | Male | 55 | 2021 | 17583 | 0.710 |
Why?
| | Female | 53 | 2021 | 18253 | 0.690 |
Why?
| | Prognosis | 17 | 2017 | 1028 | 0.680 |
Why?
| | Mediastinal Neoplasms | 2 | 2009 | 15 | 0.630 |
Why?
| | Middle Aged | 44 | 2021 | 11209 | 0.610 |
Why?
| | Carcinoma, Bronchogenic | 1 | 2015 | 14 | 0.590 |
Why?
| | Anastomosis, Surgical | 2 | 2011 | 56 | 0.540 |
Why?
| | Risk Assessment | 10 | 2021 | 806 | 0.530 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2016 | 136 | 0.530 |
Why?
| | Thoracic Surgery | 6 | 2019 | 33 | 0.510 |
Why?
| | Mediastinitis | 2 | 2009 | 7 | 0.470 |
Why?
| | Aged, 80 and over | 22 | 2018 | 5234 | 0.470 |
Why?
| | Breast Neoplasms | 2 | 2007 | 442 | 0.470 |
Why?
| | Treatment Outcome | 21 | 2017 | 3910 | 0.460 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2016 | 10 | 0.460 |
Why?
| | Solitary Pulmonary Nodule | 3 | 2015 | 14 | 0.460 |
Why?
| | Mediastinal Diseases | 1 | 2012 | 5 | 0.450 |
Why?
| | Histoplasmosis | 1 | 2012 | 9 | 0.450 |
Why?
| | Esophagectomy | 1 | 2011 | 25 | 0.450 |
Why?
| | Chemoradiotherapy | 6 | 2015 | 69 | 0.450 |
Why?
| | Practice Management, Medical | 1 | 2011 | 3 | 0.440 |
Why?
| | Survival Rate | 11 | 2021 | 465 | 0.440 |
Why?
| | Adult | 27 | 2017 | 9779 | 0.430 |
Why?
| | Airway Obstruction | 2 | 2017 | 21 | 0.420 |
Why?
| | Xanthine Dehydrogenase | 1 | 2010 | 7 | 0.410 |
Why?
| | Colon | 1 | 2011 | 155 | 0.400 |
Why?
| | Survival Analysis | 11 | 2017 | 379 | 0.400 |
Why?
| | Carbon Monoxide | 1 | 2009 | 4 | 0.400 |
Why?
| | Aspergillus flavus | 1 | 2009 | 5 | 0.390 |
Why?
| | Colorectal Neoplasms | 2 | 2009 | 125 | 0.390 |
Why?
| | Mediastinum | 1 | 2009 | 8 | 0.390 |
Why?
| | Aspergillosis | 1 | 2009 | 14 | 0.390 |
Why?
| | Predictive Value of Tests | 7 | 2014 | 637 | 0.380 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2015 | 405 | 0.370 |
Why?
| | Carcinoid Tumor | 1 | 2008 | 21 | 0.370 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2008 | 12 | 0.360 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2009 | 30 | 0.360 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 43 | 0.360 |
Why?
| | Diagnosis, Differential | 8 | 2018 | 467 | 0.360 |
Why?
| | Tomography, X-Ray Computed | 9 | 2015 | 891 | 0.350 |
Why?
| | Neoplasms, Second Primary | 1 | 2008 | 42 | 0.350 |
Why?
| | Retrospective Studies | 16 | 2017 | 3591 | 0.350 |
Why?
| | Device Removal | 2 | 2008 | 101 | 0.340 |
Why?
| | Catheterization | 2 | 2007 | 62 | 0.340 |
Why?
| | Pleural Effusion, Malignant | 1 | 2007 | 6 | 0.340 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 98 | 0.340 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2009 | 40 | 0.340 |
Why?
| | Preoperative Care | 4 | 2015 | 146 | 0.340 |
Why?
| | Genital Neoplasms, Female | 1 | 2007 | 14 | 0.330 |
Why?
| | Cohort Studies | 10 | 2018 | 2014 | 0.330 |
Why?
| | Positron-Emission Tomography | 1 | 2008 | 95 | 0.330 |
Why?
| | Early Detection of Cancer | 4 | 2019 | 91 | 0.330 |
Why?
| | Combined Modality Therapy | 8 | 2015 | 456 | 0.320 |
Why?
| | Follow-Up Studies | 11 | 2021 | 2028 | 0.300 |
Why?
| | Multiple Pulmonary Nodules | 2 | 2018 | 9 | 0.300 |
Why?
| | Multivariate Analysis | 7 | 2017 | 390 | 0.290 |
Why?
| | Immunoassay | 2 | 2018 | 45 | 0.290 |
Why?
| | Radionuclide Imaging | 4 | 2009 | 58 | 0.270 |
Why?
| | Superior Vena Cava Syndrome | 1 | 2003 | 8 | 0.260 |
Why?
| | Thoracoscopy | 5 | 2019 | 20 | 0.250 |
Why?
| | Cesarean Section | 1 | 2003 | 33 | 0.250 |
Why?
| | Disease-Free Survival | 6 | 2017 | 241 | 0.250 |
Why?
| | Lymph Node Excision | 4 | 2015 | 37 | 0.250 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 2 | 2014 | 15 | 0.250 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2003 | 52 | 0.240 |
Why?
| | Thoracic Wall | 2 | 2016 | 12 | 0.240 |
Why?
| | Technetium Compounds | 1 | 2002 | 1 | 0.240 |
Why?
| | Tin Compounds | 1 | 2002 | 1 | 0.240 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2014 | 60 | 0.240 |
Why?
| | Databases, Factual | 7 | 2021 | 391 | 0.230 |
Why?
| | Stents | 2 | 2017 | 155 | 0.230 |
Why?
| | Lung | 3 | 2021 | 171 | 0.220 |
Why?
| | Registries | 2 | 2021 | 214 | 0.220 |
Why?
| | Weight Gain | 2 | 2012 | 70 | 0.210 |
Why?
| | Tidal Volume | 1 | 2021 | 12 | 0.210 |
Why?
| | Biopsy | 4 | 2012 | 283 | 0.210 |
Why?
| | Pneumonia | 2 | 2019 | 74 | 0.200 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 580 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 5 | 2012 | 230 | 0.200 |
Why?
| | Autoantibodies | 2 | 2010 | 119 | 0.190 |
Why?
| | Esophagus | 2 | 2011 | 60 | 0.190 |
Why?
| | Gases | 1 | 2019 | 6 | 0.190 |
Why?
| | DNA Methylation | 2 | 2012 | 168 | 0.190 |
Why?
| | Histiocytoma, Benign Fibrous | 1 | 1999 | 5 | 0.190 |
Why?
| | Algorithms | 6 | 2014 | 412 | 0.190 |
Why?
| | Patient Selection | 1 | 2021 | 264 | 0.190 |
Why?
| | Mediastinoscopy | 1 | 2019 | 5 | 0.190 |
Why?
| | Feasibility Studies | 3 | 2009 | 281 | 0.190 |
Why?
| | Osteosarcoma | 1 | 1999 | 42 | 0.180 |
Why?
| | History, 20th Century | 2 | 2016 | 94 | 0.180 |
Why?
| | Intraoperative Period | 3 | 2004 | 39 | 0.180 |
Why?
| | HLA Antigens | 1 | 2018 | 20 | 0.170 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2018 | 17 | 0.170 |
Why?
| | Syndecan-1 | 1 | 2018 | 10 | 0.170 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2018 | 21 | 0.170 |
Why?
| | United States | 5 | 2021 | 2539 | 0.170 |
Why?
| | Bone Neoplasms | 1 | 1999 | 121 | 0.170 |
Why?
| | Neovascularization, Pathologic | 2 | 2015 | 68 | 0.170 |
Why?
| | Tracheomalacia | 1 | 2017 | 5 | 0.170 |
Why?
| | Nerve Growth Factors | 1 | 2018 | 46 | 0.170 |
Why?
| | Tracheal Stenosis | 1 | 2017 | 8 | 0.170 |
Why?
| | Silicones | 1 | 2017 | 14 | 0.170 |
Why?
| | Mutagens | 1 | 2016 | 2 | 0.160 |
Why?
| | Genomic Instability | 1 | 2016 | 8 | 0.160 |
Why?
| | DNA Repair | 1 | 2016 | 10 | 0.160 |
Why?
| | Sarcoma | 2 | 2009 | 139 | 0.160 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 45 | 0.160 |
Why?
| | Area Under Curve | 3 | 2014 | 79 | 0.160 |
Why?
| | Risk Factors | 7 | 2019 | 2664 | 0.150 |
Why?
| | Ribs | 1 | 2016 | 19 | 0.150 |
Why?
| | Metformin | 1 | 2016 | 21 | 0.150 |
Why?
| | Homeostasis | 1 | 2016 | 110 | 0.150 |
Why?
| | Pulmonary Artery | 2 | 1993 | 62 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 390 | 0.150 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2012 | 25 | 0.140 |
Why?
| | Cardiac Surgical Procedures | 1 | 2016 | 98 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2016 | 158 | 0.140 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 76 | 0.140 |
Why?
| | Cardiology | 1 | 2016 | 102 | 0.140 |
Why?
| | Lung Diseases, Fungal | 1 | 2015 | 10 | 0.140 |
Why?
| | Mucormycosis | 1 | 2015 | 8 | 0.140 |
Why?
| | Heart Diseases | 1 | 2016 | 102 | 0.140 |
Why?
| | Disease Progression | 4 | 2014 | 861 | 0.140 |
Why?
| | Early Medical Intervention | 1 | 2015 | 18 | 0.140 |
Why?
| | Carcinoma | 2 | 2015 | 84 | 0.140 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2014 | 10 | 0.140 |
Why?
| | Periodicals as Topic | 1 | 2015 | 46 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 378 | 0.130 |
Why?
| | Biopsy, Needle | 2 | 2008 | 117 | 0.130 |
Why?
| | Cytokines | 2 | 2014 | 364 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2014 | 24 | 0.130 |
Why?
| | Social Class | 1 | 2014 | 71 | 0.130 |
Why?
| | Thoracotomy | 5 | 2016 | 34 | 0.130 |
Why?
| | Radiotherapy, Adjuvant | 5 | 2011 | 84 | 0.120 |
Why?
| | Arteriosclerosis | 1 | 1993 | 22 | 0.120 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 11 | 0.120 |
Why?
| | Genes, p16 | 1 | 2012 | 5 | 0.120 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 224 | 0.120 |
Why?
| | Prosthesis Failure | 1 | 2017 | 534 | 0.120 |
Why?
| | Carcinoma, Small Cell | 2 | 2010 | 84 | 0.120 |
Why?
| | Extracellular Matrix | 1 | 1993 | 92 | 0.120 |
Why?
| | Immunohistochemistry | 3 | 2008 | 494 | 0.110 |
Why?
| | Prospective Studies | 6 | 2021 | 1934 | 0.110 |
Why?
| | Esophageal Stenosis | 1 | 2011 | 6 | 0.110 |
Why?
| | Stomach | 1 | 2011 | 19 | 0.110 |
Why?
| | Macrophages | 1 | 1993 | 129 | 0.110 |
Why?
| | Therapies, Investigational | 1 | 2011 | 6 | 0.110 |
Why?
| | C-Peptide | 1 | 2011 | 6 | 0.110 |
Why?
| | Group Practice | 1 | 2011 | 1 | 0.110 |
Why?
| | Forced Expiratory Volume | 2 | 2009 | 13 | 0.110 |
Why?
| | Appointments and Schedules | 1 | 2011 | 15 | 0.110 |
Why?
| | Gene Expression | 1 | 1993 | 272 | 0.110 |
Why?
| | Administrative Personnel | 1 | 2011 | 9 | 0.110 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2011 | 14 | 0.110 |
Why?
| | Young Adult | 4 | 2014 | 2277 | 0.110 |
Why?
| | Time Factors | 4 | 2019 | 1902 | 0.110 |
Why?
| | Mentors | 1 | 2011 | 41 | 0.110 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2011 | 109 | 0.110 |
Why?
| | Analysis of Variance | 4 | 2015 | 364 | 0.110 |
Why?
| | Probability | 2 | 2008 | 104 | 0.110 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2015 | 21 | 0.100 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 17 | 0.100 |
Why?
| | Length of Stay | 6 | 2016 | 377 | 0.100 |
Why?
| | Hematologic Tests | 1 | 2010 | 6 | 0.100 |
Why?
| | Protein Array Analysis | 1 | 2010 | 11 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2011 | 99 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2010 | 12 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 290 | 0.100 |
Why?
| | Antineoplastic Agents | 4 | 2014 | 274 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2010 | 22 | 0.100 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 28 | 0.100 |
Why?
| | Leadership | 1 | 2011 | 109 | 0.100 |
Why?
| | Rhabdomyosarcoma | 1 | 2009 | 7 | 0.100 |
Why?
| | Pleura | 2 | 2007 | 7 | 0.100 |
Why?
| | Adolescent | 4 | 2010 | 2667 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2010 | 42 | 0.100 |
Why?
| | Models, Statistical | 1 | 2010 | 144 | 0.100 |
Why?
| | Fibrosis | 1 | 2009 | 53 | 0.100 |
Why?
| | Animals | 5 | 2010 | 5312 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2009 | 42 | 0.090 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2010 | 101 | 0.090 |
Why?
| | Poland Syndrome | 1 | 2009 | 1 | 0.090 |
Why?
| | Thoracoplasty | 1 | 2009 | 1 | 0.090 |
Why?
| | Carcinoma, Large Cell | 1 | 2009 | 18 | 0.090 |
Why?
| | Cause of Death | 1 | 2009 | 78 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 2009 | 53 | 0.090 |
Why?
| | Smoking | 1 | 2010 | 202 | 0.090 |
Why?
| | Silicone Elastomers | 1 | 2008 | 3 | 0.090 |
Why?
| | Esophageal Fistula | 1 | 2008 | 3 | 0.090 |
Why?
| | Bronchial Fistula | 1 | 2008 | 4 | 0.090 |
Why?
| | Esophageal Perforation | 1 | 2008 | 10 | 0.090 |
Why?
| | Surgical Wound Dehiscence | 1 | 2008 | 12 | 0.090 |
Why?
| | Prosthesis Implantation | 1 | 2008 | 43 | 0.090 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2008 | 39 | 0.080 |
Why?
| | Intraoperative Care | 1 | 2008 | 58 | 0.080 |
Why?
| | Esophageal Achalasia | 1 | 2007 | 22 | 0.080 |
Why?
| | Drainage | 1 | 2007 | 55 | 0.080 |
Why?
| | Botulinum Toxins, Type A | 1 | 2007 | 34 | 0.080 |
Why?
| | Age Factors | 4 | 2014 | 943 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2008 | 82 | 0.080 |
Why?
| | Incidence | 3 | 2021 | 829 | 0.080 |
Why?
| | Atrial Fibrillation | 1 | 2010 | 197 | 0.080 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 104 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2008 | 130 | 0.080 |
Why?
| | Sepsis | 1 | 2008 | 157 | 0.080 |
Why?
| | Radiotherapy Dosage | 3 | 2015 | 149 | 0.070 |
Why?
| | Palliative Care | 1 | 2007 | 146 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2009 | 385 | 0.070 |
Why?
| | Vinblastine | 1 | 2004 | 16 | 0.070 |
Why?
| | Carboplatin | 3 | 2011 | 52 | 0.070 |
Why?
| | Paclitaxel | 3 | 2011 | 80 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2004 | 43 | 0.070 |
Why?
| | Radiography | 2 | 2013 | 717 | 0.070 |
Why?
| | Reoperation | 1 | 2008 | 938 | 0.060 |
Why?
| | Societies, Medical | 2 | 2019 | 209 | 0.060 |
Why?
| | Patient Care Planning | 1 | 2003 | 58 | 0.060 |
Why?
| | ROC Curve | 2 | 2014 | 153 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2009 | 1273 | 0.060 |
Why?
| | Hypertension, Pulmonary | 2 | 1993 | 26 | 0.060 |
Why?
| | Illinois | 2 | 2014 | 266 | 0.060 |
Why?
| | Heart Transplantation | 2 | 1993 | 50 | 0.060 |
Why?
| | Tomography, Emission-Computed | 2 | 1999 | 13 | 0.060 |
Why?
| | Graft Rejection | 2 | 1993 | 84 | 0.060 |
Why?
| | Pregnancy | 1 | 2003 | 457 | 0.060 |
Why?
| | Lung Diseases | 2 | 1999 | 54 | 0.060 |
Why?
| | Radiography, Thoracic | 2 | 2012 | 39 | 0.050 |
Why?
| | Etoposide | 2 | 2011 | 64 | 0.050 |
Why?
| | Health Services Accessibility | 2 | 2014 | 113 | 0.050 |
Why?
| | Chicago | 2 | 2016 | 955 | 0.050 |
Why?
| | Sarcoma, Small Cell | 1 | 1999 | 1 | 0.050 |
Why?
| | Aging | 1 | 2010 | 1614 | 0.050 |
Why?
| | Electrocardiography | 3 | 2003 | 209 | 0.050 |
Why?
| | Anesthesia, Epidural | 1 | 1999 | 29 | 0.050 |
Why?
| | Plasmacytoma | 1 | 1999 | 19 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 1999 | 9 | 0.050 |
Why?
| | Bupivacaine | 1 | 1999 | 55 | 0.050 |
Why?
| | Pilot Projects | 1 | 2000 | 455 | 0.050 |
Why?
| | Anesthetics, Local | 1 | 1999 | 86 | 0.040 |
Why?
| | Radiation Injuries | 1 | 1999 | 44 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2010 | 687 | 0.040 |
Why?
| | Postoperative Care | 1 | 1999 | 141 | 0.040 |
Why?
| | Endoscopy | 2 | 1997 | 181 | 0.040 |
Why?
| | Remission Induction | 2 | 2010 | 119 | 0.040 |
Why?
| | Dilatation | 1 | 2017 | 13 | 0.040 |
Why?
| | DNA End-Joining Repair | 1 | 2016 | 1 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2016 | 20 | 0.040 |
Why?
| | Protein Transport | 1 | 2016 | 42 | 0.040 |
Why?
| | Ubiquitin | 1 | 2016 | 34 | 0.040 |
Why?
| | DNA Damage | 1 | 2016 | 33 | 0.040 |
Why?
| | History, 21st Century | 1 | 2016 | 39 | 0.040 |
Why?
| | History, 19th Century | 1 | 2016 | 77 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2016 | 27 | 0.040 |
Why?
| | Procollagen | 2 | 1993 | 10 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 2016 | 41 | 0.040 |
Why?
| | Pneumonia, Bacterial | 1 | 2016 | 15 | 0.040 |
Why?
| | Muscle, Smooth, Vascular | 2 | 1993 | 24 | 0.040 |
Why?
| | Tracheostomy | 1 | 2016 | 28 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 83 | 0.040 |
Why?
| | Pain, Postoperative | 1 | 1999 | 306 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2015 | 10 | 0.040 |
Why?
| | Phenotype | 1 | 2016 | 379 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 70 | 0.040 |
Why?
| | Minnesota | 1 | 2014 | 12 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 150 | 0.030 |
Why?
| | Arrhythmias, Cardiac | 1 | 1996 | 158 | 0.030 |
Why?
| | Actuarial Analysis | 1 | 2014 | 12 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2014 | 14 | 0.030 |
Why?
| | Academies and Institutes | 1 | 2014 | 12 | 0.030 |
Why?
| | Cancer Care Facilities | 1 | 2014 | 6 | 0.030 |
Why?
| | Mutation | 1 | 2016 | 464 | 0.030 |
Why?
| | Propensity Score | 1 | 2014 | 54 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2014 | 39 | 0.030 |
Why?
| | Patient Readmission | 1 | 2015 | 129 | 0.030 |
Why?
| | Internship and Residency | 1 | 2016 | 201 | 0.030 |
Why?
| | Signal Transduction | 1 | 2016 | 588 | 0.030 |
Why?
| | Chemokine CCL3 | 1 | 2013 | 14 | 0.030 |
Why?
| | Granuloma | 1 | 2013 | 16 | 0.030 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 16 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 9 | 0.030 |
Why?
| | Collagen | 1 | 1993 | 111 | 0.030 |
Why?
| | Fibronectins | 1 | 1993 | 31 | 0.030 |
Why?
| | Coronary Circulation | 1 | 1993 | 49 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2013 | 25 | 0.030 |
Why?
| | Pulmonary Circulation | 1 | 1992 | 7 | 0.030 |
Why?
| | Respiratory Mechanics | 1 | 1992 | 10 | 0.030 |
Why?
| | Reperfusion Injury | 1 | 1992 | 9 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2013 | 42 | 0.030 |
Why?
| | Ischemia | 1 | 1992 | 35 | 0.030 |
Why?
| | Logistic Models | 1 | 2014 | 479 | 0.030 |
Why?
| | Telemetry | 1 | 1992 | 15 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2013 | 120 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2012 | 55 | 0.030 |
Why?
| | Prevalence | 1 | 2014 | 544 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2012 | 95 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 230 | 0.030 |
Why?
| | Digestive System Surgical Procedures | 1 | 2011 | 27 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2014 | 886 | 0.030 |
Why?
| | Medical Oncology | 1 | 2011 | 39 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 10 | 0.030 |
Why?
| | Choice Behavior | 1 | 2011 | 61 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 22 | 0.030 |
Why?
| | Serum | 1 | 2010 | 8 | 0.030 |
Why?
| | Antibodies, Neoplasm | 1 | 2010 | 15 | 0.030 |
Why?
| | Monomeric GTP-Binding Proteins | 1 | 2010 | 4 | 0.030 |
Why?
| | Death-Associated Protein Kinases | 1 | 2010 | 5 | 0.030 |
Why?
| | DNA Modification Methylases | 1 | 2010 | 6 | 0.030 |
Why?
| | DNA Repair Enzymes | 1 | 2010 | 9 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 53 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 54 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2010 | 42 | 0.030 |
Why?
| | Cadherins | 1 | 2010 | 38 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 53 | 0.020 |
Why?
| | Medical Records | 1 | 2010 | 40 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2010 | 60 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 108 | 0.020 |
Why?
| | Antigens, CD | 1 | 2010 | 106 | 0.020 |
Why?
| | Proteomics | 1 | 2010 | 80 | 0.020 |
Why?
| | Fluorouracil | 1 | 2009 | 88 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2010 | 94 | 0.020 |
Why?
| | Carcinoma, Renal Cell | 1 | 2009 | 46 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 107 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 78 | 0.020 |
Why?
| | Surgical Flaps | 1 | 2009 | 54 | 0.020 |
Why?
| | Dogs | 3 | 1993 | 283 | 0.020 |
Why?
| | Sutures | 1 | 2008 | 44 | 0.020 |
Why?
| | Esophageal Diseases | 1 | 2007 | 7 | 0.020 |
Why?
| | Ulcer | 1 | 2007 | 7 | 0.020 |
Why?
| | Video Recording | 2 | 1997 | 52 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2004 | 20 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2004 | 156 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 257 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2003 | 36 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 512 | 0.020 |
Why?
| | Transplantation, Heterotopic | 2 | 1993 | 13 | 0.010 |
Why?
| | Weight Loss | 1 | 2003 | 114 | 0.010 |
Why?
| | Health Status | 1 | 2003 | 249 | 0.010 |
Why?
| | African Americans | 1 | 2008 | 818 | 0.010 |
Why?
| | Vital Capacity | 1 | 1999 | 10 | 0.010 |
Why?
| | Pruritus | 1 | 1999 | 15 | 0.010 |
Why?
| | Fentanyl | 1 | 1999 | 23 | 0.010 |
Why?
| | Urinary Retention | 1 | 1999 | 12 | 0.010 |
Why?
| | Narcotics | 1 | 1999 | 33 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2003 | 410 | 0.010 |
Why?
| | Thoracic Neoplasms | 1 | 1997 | 10 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 1997 | 13 | 0.010 |
Why?
| | Pain Measurement | 1 | 1999 | 476 | 0.010 |
Why?
| | Pericardial Window Techniques | 1 | 1996 | 3 | 0.010 |
Why?
| | Treatment Failure | 1 | 1997 | 187 | 0.010 |
Why?
| | Morbidity | 1 | 1996 | 71 | 0.010 |
Why?
| | Radiotherapy | 1 | 1995 | 65 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 1995 | 129 | 0.010 |
Why?
| | Recurrence | 1 | 1995 | 389 | 0.010 |
Why?
| | Desmin | 1 | 1993 | 2 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1993 | 27 | 0.010 |
Why?
| | Actins | 1 | 1993 | 63 | 0.010 |
Why?
| | Cyclosporine | 1 | 1993 | 19 | 0.010 |
Why?
| | Acid-Base Equilibrium | 1 | 1992 | 5 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 1992 | 11 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 1992 | 24 | 0.010 |
Why?
| | Capillary Permeability | 1 | 1992 | 28 | 0.010 |
Why?
| | Body Temperature | 1 | 1992 | 74 | 0.010 |
Why?
| | Hemodynamics | 1 | 1992 | 103 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 1992 | 133 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1992 | 44 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1993 | 301 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1992 | 100 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 1992 | 163 | 0.010 |
Why?
| | Myocardium | 1 | 1992 | 183 | 0.010 |
Why?
|
|
Liptay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|